Evidence map›Paper›PMID 41112281›Full record

ArticleFrontiers in immunology2025

Explainable AI-enabled hybrid deep learning architecture for breast cancer detection.

Yan Zou, Puyang Miao

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yan ZouCollege of Mathematics and Computer Science, Chifeng University, Chifeng, China.
Puyang MiaoGeneral Surgery Thoracic Surgery, Chifeng Songshan Hospital, Chifeng, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Breast cancer stands is a leading prevalent and potential fatal infection affecting women worldwide, posing the requirement of a reliable and interpretable diagnostic system. The Deep Learning (DL) methods highly contribute towards medical imagery analysis but due to the black-box nature, its clinical adoption is limited due to lack of interpretability. Methods: This proposed work introduces a hybrid Deep Learning (DL) framework for that integrates three distinct convolutional neural network (CNN) pre-trained architectures: DENSENET121, Xception and VGG16. The proposed fusion strategy enhances feature representation and classification performance through model integration. To address the DL's black-box nature and promote clinical acceptance, the proposed framework incorporates an explainable artificial intelligence (XAI) component utilizing GradCAM++. Results: Experimental evaluation on benchmark breast cancer datasets demonstrates improved classification accuracy by approximately 13\% compared to individual models, demonstrating high performance of the fusion method with an accuracy of 97\%. Discussion: The use of fused DL model enhances the performance of the classification system offering higher accuracy and robust feature extraction. With the introduction of XAI, the cancer classification system presents interpretable results making it applicable in clinical contexts. GRADCAM++ method highlights the multiple lesions with finer edges from the ultrasound images that leads towards the model's predictions, offering transparency and aiding medical professionals in diagnostic validation.

Indexed as

Breast NeoplasmsDeep LearningArtificial IntelligenceFemaleHumansNeural Networks, Computerbreast cancerdeep learning fusionDenseNet121interpretable medical imagingultrasound analysisVGG16XAIXception

Identifiers

PMID41112281
PMCPMC12531632

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.